DKC1 and breast carcinoma: Clinical trials were performed in ovarian carcinoma [294], sarcoma [295], colorectal carcinoma [296], acute myelogenous leukaemia [297], breast cancer [298], lung cancer [299], melanoma [300] and other cancers [301] to examine the effectivity as anti-cancer therapy of pyrazofurin, a small molecule inhibitor of the orotodine-5′-monophosphate-decarboxylase (ODCase) which also inhibits DKC1.